Biological treatment in ankylosing spondylitis in the Nordic countries during 2010–2016: a collaboration between five biological registries

Abstract

Collaboration across the five Nordic biological registries regarding bDMARD use in AS is feasible but national differences in coverage, prescription patterns, and patient characteristics must be taken into account depending on the scientific question.